Last reviewed · How we verify
CYT 107
CYT 107 is a Small molecule drug developed by Cytheris SA. It is currently in Phase 1 development. Also known as: CYT107, Interleukin-7, rhIL-7.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CYT 107 |
|---|---|
| Also known as | CYT107, Interleukin-7, rhIL-7 |
| Sponsor | Cytheris SA |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Immune Reconstitution of Immunosuppressed Sepsis Patients (PHASE2)
- Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy (PHASE2)
- Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer (PHASE1)
- Safety Study of IL-7 in HIV-infected Patients (Inspire) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CYT 107 CI brief — competitive landscape report
- CYT 107 updates RSS · CI watch RSS
- Cytheris SA portfolio CI
Frequently asked questions about CYT 107
What is CYT 107?
Who makes CYT 107?
Is CYT 107 also known as anything else?
What development phase is CYT 107 in?
Related
- Manufacturer: Cytheris SA — full pipeline
- Also known as: CYT107, Interleukin-7, rhIL-7
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing